ETx-22

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameETx-22
Drug Alias NameETx-22LY4101174
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > β-glucuronide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-NECTIN4
TargetsNectin-4
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEmergence Therapeutics AG
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEli Lilly And CompanyEmergence Therapeutics AGLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A